D1 Capital Partners L.P. Acquires New Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

D1 Capital Partners L.P. bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 935,820 shares of the medical research company's stock, valued at approximately $172,752,000. Charles River Laboratories International makes up about 2.9% of D1 Capital Partners L.P.'s investment portfolio, making the stock its 11th largest position. D1 Capital Partners L.P. owned approximately 1.83% of Charles River Laboratories International as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Norges Bank bought a new stake in Charles River Laboratories International in the 4th quarter valued at $98,886,000. Wellington Management Group LLP raised its stake in shares of Charles River Laboratories International by 9.0% in the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock valued at $752,508,000 after purchasing an additional 335,658 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Charles River Laboratories International during the fourth quarter worth about $42,776,000. Invesco Ltd. boosted its position in shares of Charles River Laboratories International by 17.1% during the fourth quarter. Invesco Ltd. now owns 1,034,180 shares of the medical research company's stock worth $190,910,000 after buying an additional 151,159 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Charles River Laboratories International by 25.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 663,504 shares of the medical research company's stock valued at $122,482,000 after buying an additional 135,986 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Performance

NYSE CRL traded up $0.50 on Monday, hitting $115.16. 1,372,627 shares of the company's stock traded hands, compared to its average volume of 1,528,748. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm's 50-day moving average price is $146.73 and its two-hundred day moving average price is $170.98. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15. The firm has a market capitalization of $5.66 billion, a PE ratio of 767.73, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm's revenue for the quarter was down 1.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.46 EPS. As a group, analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analysts Forecast Growth

CRL has been the subject of several recent research reports. Mizuho reduced their price target on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. William Blair lowered Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. Barclays dropped their price target on Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their price objective for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Finally, Morgan Stanley decreased their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $182.00.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO James C. Foster bought 6,075 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the transaction, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).